Jacques Moisan

Io Therapeutics (United States) — United States

Medicine · Health Sciences

14h-index932citations67works1.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(24), Monoclonal and Polyclonal Antibodies Research(23), Cancer Immunotherapy and Biomarkers(19), Immune Cell Function and Interaction(12), Immunotherapy and Immune Responses(11)

Publications67 total

Abstract B020: Examination of a novel bi-functional TCR activating molecule in combination with docetaxel in breast and prostate cancer models
Cancer Research·2026
Abstract A028: Combination therapy with a TCR Vβ-directed bifunctional molecule, cisplatin and anti-PD-1 promotes antitumor activity in immune checkpoint blockade-refractory head and neck murine tumor models
Cancer Immunology Research·2026
916 A novel anti-TCR Vb targeted bispecific antibody in combination with a poly ADP-ribose polymerase inhibitor (PARPi) enhances anti-tumor immune response in prostate cancer models
Regular and Young Investigator Award Abstracts·2025Open Access
625 Docetaxel enhances the anti-tumor activity of a novel bi-functional TCR activating molecule in breast and prostate cancer models
Regular and Young Investigator Award Abstracts·2025Open Access
629 Triple combination therapy with a TCR Vb-directed bifunctional molecule, cisplatin and anti-PD-1 in immune checkpoint blockade-refractory head and neck murine tumor models
Regular and Young Investigator Award Abstracts·2025Open Access
Combination of a novel TCR Vβ chain-directed selective T cell activator with standard of care therapy for head and neck cancer improves antitumor responses and promotes regression of checkpoint-refractory tumor models
Journal for ImmunoTherapy of Cancer·2025Open Access
Abstract CT205: Updated clinical results, recommended phase 2 dose (RP2D) determination and translational study results for START-001: A phase 1/2 trial of invikafusp alfa, a first-in-class TCR b chain-targeted bispecific antibody in patients with anti-PD(L)1-resistant, antigen-rich solid tumors
Cancer Research·2025· 2 cited
12P A novel anti-TCR Vb targeted bispecific antibody in combination with a poly ADP ribose polymerase inhibitor (PARPi) enhances anti-tumor immune response in a prostate cancer model
ESMO Open·2025Open Access
Supp. Fig. 2 from Dual A<sub>2A</sub>/A<sub>2B</sub> Adenosine Receptor Antagonist M1069 Counteracts Immunosuppressive Mechanisms of Adenosine and Reduces Tumor Growth <i>In Vivo</i>
2024Open Access
Supp. Fig. 3 from Dual A<sub>2A</sub>/A<sub>2B</sub> Adenosine Receptor Antagonist M1069 Counteracts Immunosuppressive Mechanisms of Adenosine and Reduces Tumor Growth <i>In Vivo</i>
2024Open Access
Data from Dual A<sub>2A</sub>/A<sub>2B</sub> Adenosine Receptor Antagonist M1069 Counteracts Immunosuppressive Mechanisms of Adenosine and Reduces Tumor Growth <i>In Vivo</i>
2024Open Access
Supplementary Methods from Dual A<sub>2A</sub>/A<sub>2B</sub> Adenosine Receptor Antagonist M1069 Counteracts Immunosuppressive Mechanisms of Adenosine and Reduces Tumor Growth <i>In Vivo</i>
2024Open Access
Supp. Fig. 1 from Dual A<sub>2A</sub>/A<sub>2B</sub> Adenosine Receptor Antagonist M1069 Counteracts Immunosuppressive Mechanisms of Adenosine and Reduces Tumor Growth <i>In Vivo</i>
2024Open Access
1470 START001: a phase 1/2 study of invikafusp alfa (STAR0602), a first-in-class TCR β chain-targeted bispecific antibody, as monotherapy in patients with antigen-rich solid tumors resistant to anti-PD(L)1
2024· 1 citedOpen Access
Dual A2A/A2B Adenosine Receptor Antagonist M1069 Counteracts Immunosuppressive Mechanisms of Adenosine and Reduces Tumor Growth <i>In Vivo</i>
Molecular Cancer Therapeutics·2024· 13 cited
Abstract 2357: T cell receptor beta chain-directed Tri-specific antibody molecules retarget V-beta T cell subsets to tumors to promote potent and durable antitumor activity
Cancer Research·2024· 1 cited
Abstract 1425: Epigenetic modulation synergizes with a novel TCR β chain directed antibody-fusion molecule to suppress checkpoint-refractory tumors irrespective of MHC I status
Cancer Research·2024· 1 cited
Innate TCRβ-chain engagement drives human T cells toward distinct memory-like effector phenotypes with immunotherapeutic potentials
Science Advances·2023· 4 citedOpen Access
A T cell receptor β chain–directed antibody fusion molecule activates and expands subsets of T cells to promote antitumor activity
Science Translational Medicine·2023· 14 citedOpen Access
804 Anti-tumor effect of a novel Vβ TCR-targeting bifunctional agent in combination with anti-PD1 in checkpoint refractory murine lung cancer models
Regular and Young Investigator Award Abstracts·2023Open Access
page 1 of 4Next →

Frequent Co-authors

Madan Katragadda(12), Andrew Bayliffe(11), Zhen Su(9), Laura Carter(8), Danuta Radzioch(7), Xikui Liu(7), Chrystal M. Paulos(7), Weiping Zou(7), Jeffrey Schlom(7), Yahong Wang(6), Rodney Morgan(6), Peter L. Toogood(6), James L. Gulley(6), Sireesha Yalavarthi(6), Clotilde Bourin(6), Xiao Hu(5), Dick Bousley(5), Kinga Majchrzak(5), Clarke Taylor(5), Chad Van Huis(5)